Do Important Drugs Reach the Market Sooner?
AbstractSince the Food and Drug Administration (FDA) Amendments of 1962, the average time from a drug's first worldwide patent application to its approval by the FDA has risen from 3.5 to 13.5 years. FDA policies and manufacturers' incentives suggest that more important drugs may have reached the market sooner. To test this, we develop measures of "time to approval" and "importance," and determine how the latter affects the former. Our results indicate that more important drugs are developed and approved more rapidly than less important drugs. These results imply that the costs of approval lags have probably been overstated and challenge estimates of the returns to research and development in the pharmaceutical industry.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoArticle provided by The RAND Corporation in its journal RAND Journal of Economics.
Volume (Year): 25 (1994)
Issue (Month): 3 (Autumn)
Contact details of provider:
Web page: http://www.rje.org
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- Ludwig, Jens & Marcotte, Dave E. & Norberg, Karen, 2009.
"Anti-depressants and suicide,"
Journal of Health Economics,
Elsevier, vol. 28(3), pages 659-676, May.
- Ando, Amy, 1998. "Delay on the Path to the Endangered Species List: Do Costs and Benefits Matter," Discussion Papers dp-97-43-rev, Resources For the Future.
- Boyan Jovanovic, 2004.
2004 Meeting Papers
91, Society for Economic Dynamics.
- Tannista Banerjee & Ralph Siebert, 2013. "The Impact of R&D Cooperation on Drug Variety Offered on the Market: Evidence from the Pharmaceutical Industry," Auburn Economics Working Paper Series auwp2013-20, Department of Economics, Auburn University.
- Patricia M. Danzon & Sean Nicholson & Nuno Sousa Pereira, 2003.
"Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances,"
NBER Working Papers
9615, National Bureau of Economic Research, Inc.
- Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005. "Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances," Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
- Ernst Berndt & Iain Cockburn & Karen Grépin, 2006. "The Impact of Incremental Innovation in Biopharmaceuticals," PharmacoEconomics, Springer, vol. 24(2), pages 69-86, December.
- Andrew Epstein & Scott Johnson, 2012. "Physician response to financial incentives when choosing drugs to treat breast cancer," International Journal of Health Care Finance and Economics, Springer, vol. 12(4), pages 285-302, December.
- Fiona Scott Morton, 1997. "The Objectives of the FDA's Office of Generic Drugs," NBER Working Papers 6143, National Bureau of Economic Research, Inc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().
If references are entirely missing, you can add them using this form.